1. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ‐secretase inhibitor avagacestat. (14th December 2012) Authors: Tong, Gary; Wang, Jun‐Sheng; Sverdlov, Oleksandr; Huang, Shu‐Pang; Slemmon, Randy; Croop, Robert; Castaneda, Lorna; Gu, Huidong; Wong, Oi; Li, Hewei; Berman, Robert M.; Smith, Christina; Albright, Charles F.; Dockens, Randy Journal: British journal of clinical pharmacology Issue: Volume 75:Number 1(2013:Jan.) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ‐secretase inhibitor avagacestat. (14th December 2012) Authors: Tong, Gary; Wang, Jun‐Sheng; Sverdlov, Oleksandr; Huang, Shu‐Pang; Slemmon, Randy; Croop, Robert; Castaneda, Lorna; Gu, Huidong; Wong, Oi; Li, Hewei; Berman, Robert M.; Smith, Christina; Albright, Charles F.; Dockens, Randy Journal: British journal of clinical pharmacology Issue: Volume 75:Number 1(2013:Jan.) Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 1 randomized study of hemodynamic effects and pharmacokinetic interactions during concomitant use of rimegepant and sumatriptan in healthy adults. (28th April 2021) Authors: Croop, Robert; Ivans, Andrea; Anderson, Matt S; Stringfellow, Joseph; Bertz, Richard; Hanna, Michael; Healy, Francine; Stock, David A; Coric, Vladimir; Lipton, Richard B Journal: Cephalalgia reports Issue: Volume 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis. (2nd January 2022) Authors: Johnston, Karissa; Popoff, Evan; Deighton, Alison; Dabirvaziri, Parisa; Harris, Linda; Thiry, Alexandra; Croop, Robert; Coric, Vladimir; L'Italien, Gilbert; Moren, James Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 22:Number 1(2022) Page Start: 155 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. (February 2023) Authors: Lipton, Richard B; Blumenfeld, Andrew; Jensen, Christopher M; Croop, Robert; Thiry, Alexandra; L'Italien, Gilbert; Morris, Beth A; Coric, Vladimir; Goadsby, Peter J Journal: Cephalalgia Issue: Volume 43:Number 2(2023) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Issue 10200 (31st August 2019) Authors: Croop, Robert; Goadsby, Peter J; Stock, David A; Conway, Charles M; Forshaw, Micaela; Stock, Elyse G; Coric, Vladimir; Lipton, Richard B Journal: Lancet Issue: Volume 394:Issue 10200(2019) Page Start: 737 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Matching‐adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health‐related quality of life in the treatment of migraine. Issue 6 (22nd May 2021) Authors: Popoff, Evan; Johnston, Karissa; Croop, Robert; Thiry, Alexandra; Harris, Linda; Powell, Lauren; Coric, Vladimir; L'Italien, Gilbert; Moren, James Journal: Headache Issue: Volume 61:Issue 6(2021) Page Start: 906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomes. (1st January 2021) Authors: Johnston, Karissa M.; L'italien, Gilbert; Harris, Linda; Deighton, Alison; Popoff, Evan; Croop, Robert; Coric, Vladimir Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Novel acute therapies in the treatment of migraine: impact of re-dosing on cost–utility outcomes. (1st January 2021) Authors: Johnston, Karissa M.; L'italien, Gilbert; Harris, Linda; Deighton, Alison; Popoff, Evan; Croop, Robert; Coric, Vladimir Journal: Journal of medical economics Issue: Volume 24:Number 1(2021) Page Start: 512 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Issue 10268 (2nd January 2021) Authors: Croop, Robert; Lipton, Richard B; Kudrow, David; Stock, David A; Kamen, Lisa; Conway, Charles M; Stock, Elyse G; Coric, Vladimir; Goadsby, Peter J Journal: Lancet Issue: Volume 397:Issue 10268(2021) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗